The role of lipid disbolism in kidney disease in metabolic syndrome associated with obesity

Cite item

Full Text


Aim. To study the role of lipid metabolism impairment in renal disease in patients with metabolic syndrome associated with obesity.
Material and methods. Lipid metabolism was studied in 77 patients with metabolic syndrome (MS) aged from 17 to 63 years (mean age 48±9 years). Lipid abnormalities were analysed in groups of patients with different degree of obesity: group 1 - body mass index (BMI) 25-29.9 kg/m2 (n = 13), group 2 - BMI 30-39.9 kg/m2 (n = 49), group 3 - BMI > 40 kg/m2 (n = 15), and in groups of patients with different insulin resistance (IR) : group 1 - HOMA-IR < 2; n = 12; group 2 - HOMA-IR 2 - 4; n = 27; group 3 HOMA-IR > 4; n = 32). Correlation between plasma lipid composition abnormalities and markers of renal disease were studied with correlation analysis.
Results. Lipid disbolism in MS patients was characterized with elevated level of triglycerides, total cholesterol (TC), VLDLP cholesterol, low level of HDLP cholesterol. A significant relationship was detected between defective blood lipid composition and renal dysfunction: rise of microalbuminuria, proteinuria, creatinin, inhibition of glomerular filtration rate.
Conclusion. The changes found characterize lipid metabolism disorder as an independent factor of kidney disease in patients with MS.

About the authors

Aleksandra Aleksandrovna Kryachkova


S A Savel'eva

Irina Mikhaylovna Kutyrina

A A Kryachkova

I.M. Sechenov First Moscow Medical University

I.M. Sechenov First Moscow Medical University

S A Savelyeva

I.M. Sechenov First Moscow Medical University

I.M. Sechenov First Moscow Medical University

I M Kutyrina

I.M. Sechenov First Moscow Medical University

I.M. Sechenov First Moscow Medical University


  1. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat. Rev. Nephrol. 2009; 5: 677- 689.
  2. Bagby S. P. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J. Am. Soc. Nephrol. 2004; 15: 2775-2791.
  3. Dalrymple L. S., Kaysen G. A. The effect of lipoproteins on the development and progression of renal disease. Am. J. Nephrol. 2008; 28: 723-731.
  4. Unger R. H. Minireview: Weapons of lean body mass destruction-the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-5165.
  5. Sparks J. D., Sparks C. E. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta 1994; 1215: 9-32.
  6. Trevisan R., Nosadini R., Fioretto P. et al. Clustering of risk factors in hypertensive insuln-dependent diabetics with high sodium-lithium counter-transport. Kidney Int. 1992; 41: 855- 861.
  7. Bruno G., Gavallo-Perin P. et al. Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabet. Care 1996; 19: 43- 47.
  8. Lund-Katz S., Laplaud P. M., Phillips M. C. et al. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 1998; 37: 12867-12874.
  9. Frenasis R., Nazih H., Ouguerram K. et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein Al metabolism: akinetic study in control subjects and patients with type II diabetes mellitus. J. Clin. Endocrinol. 2001; 86: 1962-1967.
  10. Jones S. L., Close C. F. et al. Plasma lipid and coagulation factor concentration in insulin-dependent diabetic patients with microalbuminuria. Br. Med. J. 1989; 298: 487-490.
  11. Ravid M., Brosh D. et al. Main risk factors for nephroparthy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 1998; 158: 998-1004.
  12. Sammuelsson O., Attman P. et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insuffiency. J. Am. Soc. Nephrol. 1998; 9: 1482-1488.
  13. Joles J. A., Kunter U. Early mechanisms of renal injury in hypercholesterolemic or hypertriglycerdemic rats. J .Am. Soc. Nephrol. 2000; 11: 669-683.
  14. Scheuer H., Gwinner W. et al. Oxidant stress in hyperlipidemia-induced renal damage. Am. J. Physiol. Renal. Physiol. 2000; 278: 63-74.
  15. Wu Z. L., Liang M. Y., Qiu L. Q. Oxidized low-density lipoprotein decreases the induced nitric oxide synthesis in rat mesangial cells. Cell. Biochem. Funct. 1998; 16: 153-158.
  16. Chait A., Heinecke J. W. Lipoprotein modification: cellular mechanisms. Curr. Opin. Lipidol. 1994; 5: 363-370.
  17. Keane W. F. The role of lipids in renal disease: future challenges. Kidney Int. Suppl. 200; 75: S27-S31.
  18. Tan M. S., Lee Y. J., Shin S. J. et al: Oxidized low-density lipoprotein stimulates endotelin-1 release and m RNA expression from rat mesangial cells. J. Lab. Clin. Med. 1997; 129: 224-230.
  19. Nishida Y., Yorioka N., Oda H. et al. Effect of lipoproteins on cultured human mesangial cells. Am. J. Kidney Dis. 1997; 29: 919-930.

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies